COGNITE
Cognite, a globally recognized leader in industrial software, announced today that its flagship Industrial DataOps product, Cognite Data Fusion®, is now available on Google Cloud in Saudi Arabia. This strategic collaboration combines Cognite's leading data management and secure, trustworthy artificial intelligence (AI) with Google Cloud's powerful infrastructure and data analytics capabilities, enabling customers to seamlessly migrate their data to the cloud, ensuring scalability, flexibility, and security while empowering customers in Saudi Arabia with simple access to their complex industrial data.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513716575/en/
Cognite Data Fusion® Now Available on Google Cloud in Saudi Arabia (Graphic: Business Wire)
Cognite Data Fusion will deploy its own comprehensive contextualization and generative AI (gen AI) capabilities purpose-built for complex industrial data on top of Google Cloud's advanced AI and machine learning tools—a powerful combination to deliver actionable insights, improve operational efficiency, and drive digital transformation across industries such as energy, manufacturing, and logistics.
"We are thrilled to bring Cognite Data and AI offerings to Google Cloud customers in Saudi Arabia," said Dr. Francois Laborie, Executive Vice President, Cognite. "This is a significant milestone in our partnership, and as well as our commitment to the Kingdom. The power of data and AI, from Cognite and Google Cloud, enables industry transformation via solutions that deliver business value to our customers."
"We are excited to partner with Cognite to bring their advanced industrial data platform to Google Cloud customers in Saudi Arabia," said Abdul Rahman Al Thehaiban, Managing Director, Middle East, Turkey and Africa, Google Cloud. "By leveraging Google Cloud's scalable and secure infrastructure, Cognite Data Fusion will enable customers to harness the power of their data to make smarter business decisions and accelerate their digital transformation journey."
Cognite Data Fusion’s best-of-breed gen AI capabilities tailored for industrial use cases enable customers to generate synthetic data, simulate scenarios, and optimize operations, ultimately improving decision-making and business outcomes.
In the Kingdom and the wider MENA region, Cognite Data Fusion is brought to the market by CNTXT, a joint venture between Saudi Aramco and Cognite. This partnership combines CNTXT's deep understanding of the regional industrial landscape with Cognite's cutting-edge technology, providing customers with tailored solutions that address their specific needs and challenges. "Cognite Data Fusion is poised to revolutionize how the Kingdom’s industries harness insights from their data. Cognite Data Fusion offers world-leading gen AI capabilities tailored for industrial sectors", said Abdullah Jarwan, CEO of CNTXT.
Cognite Data Fusion on Google Cloud is now available for customers in Saudi Arabia. For more information, visit www.cntxt.com.
About CNTXT:
CNTXT, a joint venture between Saudi Aramco and Cognite, is a leading digital transformation company headquartered in Riyadh, Saudi Arabia. With a mission to empower organizations through technology and innovation, CNTXT leverages strategic partnerships and a network of resellers to accelerate digital transformation across public and private sectors in the Kingdom.
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power and renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable and more profitable. Cognite provides a user-friendly, secure, and scalable industrial DataOps platform, Cognite Data Fusion®, that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and X (Twitter).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513716575/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom